CleanCap EPO mRNA (5moU), 5 x 1.00 mg

EPO mRNA encodes the human erythropoietin (EPO) protein, a hormone that controls erythropoiesis, or red blood cell production. EPO also plays a role in wound healing and the brain's response to neural injury. Kariko et al. showed that transfection of EPO mRNA in vivo resulted in significant increases of both reticulocyte counts and hematocrits. This mRNA is capped usingCleanCap® Reagent AG, TriLink's patented co-transciptional capping technology, which results in the naturally occurring Cap-1 structure with >95% capping efficiency. It is manufactured using TriLink'sCleanScriptTM method*, polyadenylated, modified with5-methoxyuridine, and optimized for mammalian systems. It mimics a fully processed mature mRNA. CleanCap® Reagent AG produces a base-modified Cap-1 mRNA, which shows superiorin vivoactivity compared to Cap-0 mRNA produced by legacy capping methods such as mCap or anti-reverse cap analog (ARCA) . 5-methoxyuridine is a modified uridine that can reduce immunogenic response and enhance translational efficiency of mRNAs. These properties can result in safer mRNA and increased protein expression. CleanScriptTM method is TriLink's proprietaryin vitrotranscription process that is optimized to minimize dsRNA formation and increase mRNA activityinvivo. *Starting April 30th, 2024